Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,854
  • Shares Outstanding, K 71,030
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,790 K
  • EBIT $ -122 M
  • EBITDA $ -120 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.39

Options Overview Details

View History
  • Implied Volatility 137.39% (-11.84%)
  • Historical Volatility 50.46%
  • IV Percentile 75%
  • IV Rank 12.93%
  • IV High 636.43% on 01/06/25
  • IV Low 63.26% on 05/20/25
  • Expected Move (DTE 13) 0.6375 (35.42%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 7
  • Volume Avg (30-Day) 156
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 6,836
  • Open Int (30-Day) 21,450
  • Expected Range 1.1625 to 2.4375

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.37
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +5.88%
on 11/21/25
2.0500 -12.20%
on 11/11/25
-0.1500 (-7.69%)
since 11/05/25
3-Month
1.7000 +5.88%
on 11/21/25
2.7400 -34.31%
on 10/16/25
-0.4600 (-20.35%)
since 09/05/25
52-Week
1.3100 +37.40%
on 03/26/25
2.7400 -34.31%
on 10/16/25
-0.8400 (-31.82%)
since 12/05/24

Most Recent Stories

More News
Nkarta to Participate in Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 1.8000 (-2.17%)
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights 

Enrollment now underway in second dose-escalation cohort  Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in a September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected...

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 1.8000 (-2.17%)
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

NKTX : 1.8000 (-2.17%)
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

NKTX : 1.8000 (-2.17%)
Nkarta to Participate in an April Investor Conference

NKTX : 1.8000 (-2.17%)

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 1.9383
2nd Resistance Point 1.9067
1st Resistance Point 1.8533
Last Price 1.8000
1st Support Level 1.7683
2nd Support Level 1.7367
3rd Support Level 1.6833

See More

52-Week High 2.7400
Fibonacci 61.8% 2.1937
Fibonacci 50% 2.0250
Fibonacci 38.2% 1.8563
Last Price 1.8000
52-Week Low 1.3100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar